3 Nuclear Power Stocks Worth Owning as the AI Power Crunch Builds
Hyperscalers are signing multi-decade nuclear contracts as grid capacity tightens, and three stocks give investors very different exposure to that trade, with one belonging in the speculative bucket only.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
AI is turning nuclear baseload into the most contested resource on the grid, and hyperscalers are lining up multi-decade contracts to lock it down.
The pressure is quantifiable: PJM’s capacity auction cleared at $329.17/MW-day for 2026/27 and $325/MW-day for 2028/29, with combined 2026 hyperscaler CapEx guidance topping $710 billion.
Three U.S.-listed names give investors distinct angles on that trade, but they are not equivalent risks. One is a cash-generating merchant operator. One is a profitable, dividend-paying contractor. One is a pre-revenue developer that belongs in the speculative bucket only.
Constellation Energy: Largest US Nuclear Fleet Signing the Hyperscaler Deals
Constellation Energy (NASDAQ:CEG | CEG Price Prediction) is the anchor position in this segment. It operates the largest U.S. nuclear fleet and, following the January 2026 close of the Calpine acquisition, is now the largest private power producer in the world. This is a cash-generating merchant IPP with an established earnings base.
The Q2 2026 earnings report tells the story. Constellation reported adjusted operating earnings of $2.55 per share and raised full-year guidance to $11.50 to $12.50 per share. More importantly, the company signed approximately 920 megawatts of long-term nuclear contracts during the quarter, with an average duration of 18 and a half years and investment-grade counterparties. Roughly 30% of clean baseload output is now under long-term contract. The Crane Clean Energy Center restart is targeting 2027, with the NRC fuel license already approved. Nuclear operations delivered a 93% capacity factor in the quarter.
The bull case: Existing nuclear is being repriced as a premium product, PJM capacity prices are lifting the entire revenue stack, and the Nuclear Production Tax Credit provides a floor. Shares are down nearly 31% year to date, which has taken some of the froth out of a name that ran hard in 2024 and 2025.
The risk: Regulation. PJM’s proposed Reliability Backstop Procurement and Interim Resource Adequacy Service frameworks remain unresolved, and the Illinois ZEC program ends in May 2027. Calpine integration also introduces near-term execution complexity.
BWX Technologies: The Only Big Nuclear Manufacturer Left Standing
BWX Technologies (NYSE:BWXT) is the picks-and-shovels play. It supplies naval nuclear propulsion to the US Navy and manufactures commercial nuclear components, field services, and fuel handling equipment. This is a profitable, dividend-paying contractor with multi-year backlog visibility, and it sits in a different risk bucket than a merchant generator or a developer.
Q2 2026 revenue was $902 million, up 18% year over year, with adjusted EPS of $1.07 marking the fifth consecutive EPS beat. Commercial operations revenue grew 72%, including 33% organic growth. Backlog ended the quarter at $8.4 billion, up 40% year over year, with a trailing 12-month book-to-bill of 1.7 times. Management raised full-year revenue guidance to approximately $3.8 billion and free cash flow guidance to $345 million to $360 million. The Precision Components Group acquisition closed July 1, 2026, adding US commercial nuclear manufacturing capacity.
CEO Rex Geveden framed the setup bluntly, saying the “industry is in the early stages of a multi-decade super cycle of growth” and that BWXT was “kind of the last man standing in commercial” nuclear manufacturing. He also flagged “a credible opportunity to secure at least one new build nuclear equipment order before the year end” across AP1000, X300, and additional SMR opportunities at Darlington.
The bull case: Any reactor built in North America over the next decade, large or small, plausibly runs through BWXT’s fabrication footprint. Shares are down nearly 24% year to date, offering a more reasonable entry than earlier in the year.
The risk: Federal budget uncertainty. Naval propulsion revenue depends on shipbuilding funding cadence, and commercial customer capex timing on SMRs is inherently lumpy.
Oklo: A Speculative, Pre-Revenue SMR Position That Belongs in a Small Allocation Only
Oklo (NYSE:OKLO) is a fundamentally different animal from the first two names and must be treated that way. It is a pre-revenue small modular reactor developer with a development-stage, cash-burning profile. It carries meaningfully higher risk than Constellation or BWXT, and it is only size-appropriate as a small speculative allocation.
The company’s Aurora powerhouse design has been expanded to 75 MW, with first commercial power targeted late 2027 to early 2028. Oklo’s customer pipeline includes a 12 GW master power agreement with Switch targeting delivery by 2044, plus a letter of intent with Equinix for up to 500 MW with a $25 million prepayment. Investors must be clear-eyed that these are largely non-binding LOIs and master agreements, not signed take-or-pay PPAs. Groves reached first criticality in early August 2026, and the company ended the quarter with $3 billion in cash and marketable securities. Management raised 2026 cash-use guidance to $120 million to $150 million for operations and $400 million to $500 million for property, plant, and equipment.
The bull case: Optionality. an integrated platform across power, fuel, and isotopes, direct hyperscaler alignment, and a supportive regulatory backdrop under the ADVANCE Act. Shares reflect the volatility of the profile, down more than 51% year to date and down more than 66% over the past year.
The risk: Oklo has no operating commercial project, no signed take-or-pay revenue, ongoing NRC execution risk, and will likely need additional financing to build plants. First commercial power is a 2027 to 2028 event at the earliest. If the timeline slips or licensing stalls, the equity has a long way to fall.
Positioning the 3
Constellation offers core exposure to nuclear baseload getting repriced by hyperscaler demand, backed by real cash flows and signed long-dated contracts. BWXT is the manufacturing choke point that benefits regardless of which reactor design wins. Oklo represents a small, speculative call option on advanced nuclear, sized accordingly and never confused with the other two.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
